Author name: thilina.s.perera1@gmail.com

We are thrilled to share the great success of the Champlain-Lennoxville Pink Games Fundraiser, which raised an outstanding $8,000 for SaRC-Q. This remarkable achievement highlights the power of community and collective effort in supporting vital cancer research. The annual Pink Games brought together the Champlain Students’ Association, the Cougars Athletics teams, and many other dedicated members of the Champlain-Lennoxville community. Their enthusiasm and determination not only made this year’s event a success but also doubled the amount raised in 2023. The funds raised will contribute significantly to advancing sarcoma cancer research and providing much-needed support to individuals and families affected by this rare disease. At SaRC-Q, we believe that initiatives like these are pivotal in raising awareness and driving meaningful progress in the fight against sarcoma. We extend our heartfelt thanks and congratulations to the Champlain Students’ Association, the Cougars Athletics teams, and everyone who participated in or contributed to this inspiring fundraiser. Your dedication and generosity inspire us to continue our mission to improve lives through research and innovation. Thank you for making a difference. Together, we are stronger.

We are thrilled to announce that a Phase III, multicenter, randomized, double-blind clinical study is now open for recruitment. This trial focuses on assessing the safety and efficacy of Emactuzumab, a promising investigational therapy, compared to a placebo in patients diagnosed with Tenosynovial Giant Cell Tumor (TGCT). About the Study TGCT, also known as Tumeur à Cellules Géantes de la Gaine Synoviale (TCGGS) in French, is a rare and potentially debilitating condition. This trial aims to explore a new therapeutic option that could significantly improve outcomes for patients. Who Can Participate? We are looking for individuals diagnosed with TGCT who meet the eligibility criteria. This is a unique opportunity to contribute to advancing medical research and potentially benefit from cutting-edge treatment. Why Join? How to Get Involved If you or someone you know is living with TGCT, visit our dedicated trial page to learn more about the study, eligibility requirements, and how to participate. Let’s advance the future of TGCT treatment together!

We’re excited to announce that a new Phase III clinical trial is now open for recruitment. This study is focused on patients with advanced gastrointestinal stromal tumors (GIST) who have previously been treated with Imatinib. Study Overview: This important research seeks to provide valuable insights into new treatment options for advanced GIST, a condition that can be challenging to manage. If you or someone you know is eligible and interested in participating, please reach out for more details. Stay tuned for updates on this promising study and its progress!

On June 17, professionals, patients, families, and foundations gathered at CHU Sainte-Justine for a day dedicated to sarcoma research. Together, we set clear goals to improve data sharing and support emerging technologies. Working Hand in Hand: Thanks to the Sarcoma Network Quebec and SaRC-Q, we are breaking down barriers to advance together with the unique energy and support of families and foundations. Concrete Goals: We set goals and we strive to reach them. We aim to create a forum for exchanging difficult cases, pool biological data, and collaborate with veterinary oncologists to drive therapeutic advancements. Collective Energy: Your support is our inspiration. Together, we are a leading force in sarcoma research. We will continue this momentum for a brighter future and this event will be a yearly success!

We are excited to share groundbreaking research co-authored by Dr. Jonathan Noujaim and Dr. Ramy Saleh, co-founders of SaRC-Q, that delves into the real-world application of tyrosine kinase inhibitors (TKIs) sorafenib and pazopanib in treating desmoid tumors (DT). This retrospective study, the largest of its kind, offers significant insights into long-term patient outcomes and the efficacy of these treatments. Study Overview: The study reviewed data from 142 patients diagnosed with DTs and treated with either sorafenib or pazopanib between 2011 and 2022 across 11 institutions. Patient histories, responses to therapy, and toxicities were meticulously recorded and analyzed using Kaplan-Meier and log-rank tests. This retrospective study represents the largest cohort of DT patients treated with sorafenib or pazopanib to date. Key Findings: Conclusions: This study underscores the potential of sorafenib and pazopanib in managing desmoid tumors effectively. It also highlights the need for further research to determine the optimal treatment duration, especially for patients with stable disease. Dr. Noujaim and Dr. Saleh\’s contribution to this research marks a significant milestone in DT treatment, providing hope and direction for future therapies. For those interested in exploring the full details of this study, please visit the article on ScienceDirect: Real-World Experience of Pazopanib and Sorafenib in Patients with Desmoid Tumors. Stay tuned to SaRC-Q for more updates on our ongoing efforts to advance cancer research and improve patient outcomes.

We are delighted to share that the incredible story of Sooran Noroozi\’s resilience and the launch of the Sooran Noroozi Sarcoma Research Award has been prominently featured on Global News. This award, established in memory of Sooran Noroozi, celebrates his legacy of courage and determination in the face of sarcoma. It is a tribute to the unwavering dedication of our medical professionals, including Dr. Ramy Saleh, Dr. Joseph Petrucelli, Dr. Anthony Bozzo and other experts, who tirelessly push the boundaries of science to improve patient outcomes. Sooran\’s journey, battling sarcoma while eagerly awaiting the birth of his daughter, is a poignant reminder of the strength and hope that permeates our research community. His story reflects the resilience and spirit of countless individuals affected by sarcoma, inspiring us to continue our mission of advancing sarcoma research and providing compassionate care. We extend our heartfelt gratitude to Global News for spotlighting this meaningful initiative and highlighting the collaborative efforts that drive our ongoing work in sarcoma research. Together, we strive to make a difference and honor Sooran\’s legacy every step of the way.

Join the New Polaris Clinical Trial – Phase III study now recruiting patients with Leiomyosarcoma! Discover cutting-edge treatments and contribute to advancing sarcoma research. Contact us for more information and eligibility criteria. Visit the Clinical Trials table for more information.

CQDM announces funding for three cancer research projects, supported by the Québec government grant. These projects aim to enhance cancer treatment efficacy and reduce side effects. They include Theratechnologies\’ platform for colorectal cancer, Saydi Biotech\’s MDM2 inhibitor for various cancers, and Roche Canada\’s use of circulating tumor DNA for monitoring DLBCL patients. Dr. Ramy Saleh, along with other collaborators, plays a crucial role in Saydi Biotech\’s project, emphasizing Québec\’s leadership in innovative cancer research.

This group has been created by SaRC-Q to offer a space for sharing, support, and mutual assistance to all those living with GIST (Gastrointestinal Stromal Tumor) in Quebec and Canada. Our goal is to create a supportive and caring community where everyone feels supported and understood. Together, we can help each other overcome the challenges related to GIST and find resources to improve our quality of life. SaRC-Q will be sharing advancements in GIST treatments and insights about this sarcoma, as well as scientific and medical data.

Trials involving Tenosynovial Giant Cell Tumor (TGCT) in Canada now welcome participants from all regions across the country. If you would like to participate in these clinical trials, lodging and transportation are offered to facilitate the participation of eligible individuals. This assistance aims to ensure that geographical distance does not pose a barrier for patients interested in contributing to TGCT research. Prospective participants are encouraged to contact the trial coordinators or investigators to inquire about specific details regarding lodging and transportation arrangements for the particular trial they are interested in.